Skip to Content
  1. All products
  2. Weight Management
  3. Retatrutide
  4. Weight Management
Pricelist: Default Pricelist Pricelist
Pricelist: Default Pricelist Pricelist
Retatrutide

Retatrutide

Lyophilized Vial · Subcutaneous Administer with a 0.5mL insulin syringe (50 units = 0.5mL). Always round to nearest 0.5-1 unit for simplicity. 99% Purity · USP Grade
99% Purity
PHYSICIAN USE ONLY
$ 212.00 $ 212.00

Format
💉 vial
  • Strength
Add to cart
Terms and Conditions
30-day money-back guarantee
Shipping: 2-3 Business Days
Clinical Description

Advanced weight management, metabolic optimization, appetite regulation, fat loss for patients who have plateaued with GLP-1 or dual agonist therapies

Retatrutide es un agonista triple de próxima generación que activa los receptores GLP-1, GIP y glucagón. Este enfoque de triple objetivo favorece una pérdida significativa de grasa, la optimización metabólica y la regulación del apetito. Actualmente se está estudiando como uno de los péptidos más eficaces para el control metabólico y el control avanzado del peso, especialmente en pacientes que se han estancado con GLP-1 o terapias con agonistas duales.

Clinical Indications
Severe ObesityMetabolic SyndromeType 2 DiabetesBody RecompositionCardiovascular Risk Reduction
Recommended Stacking Protocols
✓
Mazdutide
For rotational use or enhanced receptor stimulation
✓
KPV
Supports inflammation control and gut health
✓
AOD-9604
Boosts fat burning and thermogenesis

Mechanism of Action - Weight Management / Metabolic Pathway

Triple Receptor Agonism
Simultaneously activates GIP, GLP-1, and glucagon receptors for unmatched metabolic impact.
Energy Expenditure Boost
Glucagon receptor activation increases basal metabolic rate and thermogenesis beyond GLP-1 alone.
Central Appetite Control
Combined incretin signaling produces profound appetite suppression.
Hepatic Fat Reduction
Dual incretin + glucagon action drives significant visceral and hepatic fat clearance.
Starting Dose
0.5mg once weekly
Initiation phase for tolerance and baseline response.
Titration
Increase by 0.5-1mg every 2-4 weeks PRN
Maintenance Range
1mg-3mg weekly
Adjust based on objective outcomes and physician review.
Suggested Dosing Notes

Dosis inicial:0,5 mg una vez a la semana

Valoración:Aumentar de 0,5 a 1 mg cada 2 a 4 semanas PRN

Rango de mantenimiento típico:1 mg-3 mg semanal

Period Dose Phase Clinical Notes
Starting Dose 0.5mg once weekly initiation Initial dose for treatment initiation
Titration Increase by 0.5-1mg every 2-4 weeks PRN escalation Gradual increase as needed based on response
Maintenance Range 1mg-3mg weekly maintenance Typical maintenance dose range
Week 17+ 8–12 mg maintenance Maximum studied dose. Titrate to response.
Preparation Protocol
  1. Retatrutide se suministra como polvo liofilizado.
  2. Retatrutide debe reconstituirse con agua bacteriostática antes de su uso.
  3. Elija el volumen de reconstitución según el tamaño del vial para facilitar la dosificación.
1
Lyophilized Powder
Retatrutide is provided as a lyophilized powder.
2
Reconstitution Required
Retatrutide must be reconstituted with Bacteriostatic Water prior to use.
3
Choose Volume
Choose your reconstitution volume based on the vial size for easy dosing.
4
Reconstitute the Vial
Wipe stopper with alcohol swab. Inject BW slowly along the glass wall — never directly onto the powder. Allow liquid to run down the sides.
⚠️ Do not shake. Gently swirl or roll between palms (30–60 sec). Shaking causes irreversible peptide degradation.
5
Inspect & Store
Solution should be clear and colorless or slightly yellow. Discard if cloudy or particulate. Store reconstituted at 2–8°C, use within 28 days. Label with date.
Reconstitution & Dosing Guide
Standard 1 mL insulin syringe: 100 units = 1 mL

Total Peptide: 20 mg
BW: 2 mL
Concentration: 10mg/mL (100mcg per unit)
Dose Units to Draw Volume (mL) Approx. Supply
0.5mg 5 units - 25 weeks
1mg 10 units - 20 weeks
1.5mg 15 units - 15 weeks
2mg 20 units - 10 weeks
2.5mg 25 units - 8 weeks
3mg 30 units - ~6.5 weeks
Identity
  • Name: Retatrutide
  • Product Type: Vial | Subcutaneous Injection
  • CAS Number: 2381935-79-9
  • Available Strengths: 20mg, 30mg, 40mg
  • Molecular Formula: Investigational
  • Molecular Weight: ~4,900 Da (est.)
  • Sequence / Type: GIP/GLP-1/Glucagon Triple Agonist
  • Available Strengths: 5mg, 10mg, 15mg, 20mg, 30mg, 60mg, 100mg
Quality & Purity
  • Purity: 99%+
  • Purity: ≥ 99%
  • Endotoxin: ≤ 1 EU/mg
  • Appearance: White lyophilized powder
  • Solubility: Bacteriostatic water
Storage & Handling
  • Storage: Refrigerate after reconstitution (2-8°C)
  • Syringe Tip: Administer with a 0.5mL insulin syringe (50 units = 0.5mL). Always round to nearest 0.5-1 unit for simplicity.
  • Pre-use Storage: -20°C (long-term) / 2–8°C (short)
  • Post-Reconstitution: 2–8°C · Up to 28 days
  • Shelf Life: 18 months from manufacture

Timing: Use consistent administration timing for stable protocol tracking.

Storage: Administer with a 0.5mL insulin syringe (50 units = 0.5mL). Always round to nearest 0.5-1 unit for simplicity.

Frequency: StartingDose:O.5mgonceweekly Typical Maintenance Range:1mg-3mg Weekly

Cycle: Titration:Increaseby0.5-1mg every2-4WeeksPRN

Injection Sites: Rotate approved injection sites to reduce local irritation risk.